Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21912594 | 0.80 | AURKA (0.34) | AURKATTKAURKBINCENP | |
| SCHEMBL17041803 | 0.80 | EP300 (0.33) | EP300KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL24871115 | 0.78 | — | — | |
| SCHEMBL12994242 | 0.78 | PI4KA (0.33) | EP300ALDH1A1 | |
| SCHEMBL2515269 | 0.77 | KDM4E (0.34) | KDM4EALDH1A1HPGD | |
| SCHEMBL15456757 | 0.77 | EP300 (0.34) | EP300KDM4EALDH1A1 | |
| SCHEMBL16869991 | 0.77 | AURKA (0.33) | AURKATTKAURKBINCENP | |
| SCHEMBL13586939 | 0.77 | — | — | |
| SCHEMBL1225898 | 0.77 | ALB (0.38) | EP300 | |
| SCHEMBL2194330 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111836823-B | Beta-modified phosphate compound precursor, beta-modified phosphate compound, reaction inhibitor, and pharmaceutical product containing these compounds, and reaction inhibition method | 国立研究开发法人科学技术振兴机构 | 2023-06-30 | — | — | CN | claimed |
| CN-111836823-A | Precursor of beta-modified phosphate compound, reaction inhibitor, pharmaceutical containing these compounds, and method for inhibiting reaction | 国立研究开发法人科学技术振兴机构 | 2020-10-27 | — | — | CN | claimed |
| WO-2019172394-A1 | β-MODIFIED PHOSPHORIC ACID COMPOUND PRECURSOR, β-MODIFIED PHOSPHORIC ACID COMPOUND, REACTION INHIBITOR, AND MEDICINE INCLUDING SAME, AND REACTION INHIBITION METHOD | 国立研究開発法人科学技術振興機構 | 2019-09-12 | — | — | WO | claimed |
| EP-1895840-A2 | P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES | Inspire Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2007002945-A2 | P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES | INSPIRE PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-12037636-B2 | Polynucleotide synthesis method, kit and system | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-07-16 | — | — | US | disclosed |
| US-12037636-B2 | Polynucleotide synthesis method, kit and system | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-07-16 | — | — | US | disclosed |
| WO-2024137765-A1 | TRANSITION-METAL CATALYST COMPOSITIONS AND METHODS FOR SEQUENCING BY SYNTHESIS | ILLUMINA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118043333-A | Method and apparatus for cutting nucleic acid strand, and method and apparatus for producing double-stranded DNA | 国立研究开发法人科学技术振兴机构 | 2024-05-14 | — | — | CN | disclosed |
| CN-117858885-A | Method and device for purifying nucleotide, and hydrophobic reagent and hydrophobic substrate | 国立研究开发法人科学技术振兴机构 | 2024-04-09 | — | — | CN | disclosed |
| CN-117295528-A | Artificial nucleic acid and nucleic acid delivery method using the same | 国立研究开发法人科学技术振兴机构 | 2023-12-26 | — | — | CN | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| EP-0586523-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0504279-A4 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | — | 1993-02-17 | — | — | EP | disclosed |
| WO-1992020816-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| US-4232154-A | Carbocyclic analogs of cytosine nucleosides exhibiting antiviral and antineoplasticactivity | UNITED STATES OF AMERICA (US) | 1980-11-04 | — | — | US | disclosed |
| US-4177348-A | VIRICIDES, ANTINEOPLASTIC, ANTILEUKEMIA, ANTICANCER | UNITED STATES GOVERNMENT (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | EP300 4874/4885KDM4E 3297/4885ALDH1A1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.